Actavis (ACT) Reports Positive Top-Line Data from Two Ceftazidime-Avibactam Phase 3s
Tweet Send to a Friend
Actavis (NYSE: ACT) confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
